Business Context and Reporting Period
Company: Synaptogenix, Inc. (SNPX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Synaptogenix is a biopharmaceutical company focused on developing Bryostatin-1 for Alzheimer's disease (AD) and other neurodegenerative disorders. The company operates as a smaller reporting company and emerging growth company. As of September 30, 2024, the company had 1,355,613 shares of common stock outstanding (adjusted for a 1-for-25 reverse stock split effective April 4, 2024).
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(5,742,013) | $(763,203) | $(7,222,021) | $(5,042,535) |
| Net Loss Attributable to Common Stockholders | $(6,048,738) | $(361,425) | $(7,902,940) | $(12,549,812) |
| Operating Expenses | $1,359,669 | $1,429,792 | $4,632,130 | $6,181,446 |
| Cash and Cash Equivalents (Ending) | $19,625,780 | $31,727,549 | $19,625,780 | $31,727,549 |
| Working Capital | $21,939,418 | $26,256,291 | $21,939,418 | $26,256,291 |
| Derivative Liability | $6,118,000 | $1,113,000 | $6,118,000 | $1,113,000 |
| Warrant Liability | $3,251,000 | $140,000 | $3,251,000 | $140,000 |
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss for the three months ended September 30, 2024, increased to $5.74 million from a loss of $0.76 million in the same period in 2023. This was primarily driven by a $3.8 million loss on the issuance of Series C Preferred Stock, increased fair value adjustments on warrant and derivative liabilities, and warrant issuance costs.
- Operating Expenses: Total operating expenses decreased by 4.9% in Q3 2024 compared to Q3 2023, and by 25.1% on a year-to-date basis. This reduction is attributed to lower general and administrative costs (specifically legal fees and stock-based compensation) and the conclusion of the Phase 2 AD clinical trial in late 2023.
- Capital Structure Changes:
- Series B Redemption: The company fully satisfied its obligations to Series B preferred stockholders, redeeming approximately $8.8 million in principal and accrued dividends during the nine months ended September 30, 2024.
- Series C Issuance: In September 2024, the company completed a registered direct offering and concurrent private placement of Series C Convertible Preferred Stock, raising approximately $4.5 million in net proceeds. This issuance resulted in significant non-cash losses due to the fair value of embedded derivatives and warrants exceeding proceeds.
- Cash Position: Cash and cash equivalents decreased by approximately $9.0 million during the nine months ended September 30, 2024, primarily due to operating cash burn and the redemption of Series B preferred stock, partially offset by proceeds from the Series C offering.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects current cash resources (approximately $18.3 million as of the filing date) to be sufficient to support projected operating requirements for at least the next 12 months. This includes the continuing development of Bryostatin-1 and the initiation of a Multiple Sclerosis (MS) trial.
- Capital Needs: The company anticipates needing additional capital to complete all potential AD clinical trials and pursue other development projects. Future financing may be dilutive or involve restrictive covenants.
- Clinical Developments:
- Alzheimer's Disease: The Phase 2 confirmatory study (Study #204) did not achieve statistical significance on the primary endpoint. However, post-hoc analysis showed statistical significance in the most severe AD patient stratum (MMSE 10-14).
- Multiple Sclerosis: A Phase 1 trial with Cleveland Clinic is ongoing, with 3 subjects enrolled and 2 dosed as of September 30, 2024.
- Fragile X: An IND has been filed with the FDA but is currently on clinical hold pending further analytics.
- Internal Controls: The company disclosed that its disclosure controls and procedures are not effective due to material weaknesses, including inadequate segregation of duties, ineffective period-end financial reporting processes, and ineffective IT general controls.
- Risk Factors: Key risks include the inability to secure additional funding, the limited supply of raw materials (bryostatin), regulatory hurdles, and the potential for significant dilution from future equity offerings.
Investor Verification Checklist
- Series C Terms: Verify the specific redemption schedule (quarterly installments starting October 31, 2024) and the 107% redemption premium for Series C Preferred Stock.
- Derivative Liability Volatility: Monitor the fair value of the $6.1 million derivative liability and $3.3 million warrant liability, as fluctuations in the company's stock price will directly impact reported net income/loss.
- Cash Burn Rate: Assess the sustainability of the current cash balance against the $3.7 million operating cash burn observed in the first nine months of 2024.
- Internal Control Remediation: Review future filings for progress in remedying the material weaknesses in internal controls over financial reporting.
- Clinical Trial Status: Confirm the resolution of the FDA clinical hold on the Fragile X IND and the enrollment progress of the MS Phase 1 trial.